{
    "name": "tazarotene",
    "comment": "Rx",
    "other_names": [
        "Avage",
        "Tazorac",
        "Fabior",
        "Arazlo"
    ],
    "classes": [
        "Acne Agents",
        "Topical",
        "Antipsoriatics",
        "Topical",
        "Retinoid-like Agents",
        "Topical"
    ],
    "source": "https://reference.medscape.com/drug/avage-tazorac-tazarotene-topical-343554",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies with use in pregnant women",
            "Contraindicated in females who are or may become pregnant",
            "Based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy; safety in pregnant females has not been established; the potential risk to the fetus outweighs the potential benefit to the mother during pregnancy; therefore, discontinue as soon as pregnancy is recognized",
            "Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed child from therapy or from the underlying maternal condition"
        ],
        "specific": [
            {
                "type": "Females of childbearing potential",
                "description": [
                    "Females of child-bearing potential should be warned of potential risk and use adequate birth- control measures when the drug is administered; the possibility that a female of child-bearing potential is pregnant at time of institution of therapy should be considered",
                    "  ",
                    "  ",
                    "Pregnancy testing is recommended within 2 weeks before initiating therapy, which should begin during a menstrual period",
                    "  ",
                    "  ",
                    "Based on animal studies, fetal harm may occur when administered to a pregnant woman",
                    "Advise to use effective contraception during treatment "
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "To minimize potential exposure to the breastfed infant via breast milk, use for the shortest duration possible while breastfeeding",
                    "Advise breastfeeding patients not to apply directly to the nipple and areola to prevent direct infant exposure"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for therapy and any potential adverse effects on the breastfed child from therapy or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Propellant in foam is flammable; avoid fire, flame, and/or smoking during and immediately following application"
            ],
            "specific": [
                {
                    "type": "Local irritation",
                    "description": [
                        "Excessive irritation in skin of certain sensitive individuals; local reactions (including blistering and skin desquamation, pruritus, burning, erythema)and hypersensitivity adverse reactions (including urticaria) reported with topical application",
                        "If adverse reactions occur, consider discontinuing the medication or reducing dosing frequency, as appropriate, until integrity of skin is restored; alternatively, patients withpsoriasis who are being treated with 0.1% concentration can be switched to lower concentration; frequency of application should be closely monitored by careful observation of clinical therapeutic response and skin tolerance; therapy can be resumed, or drug concentrationor frequency of application can be increased as patient becomes able to tolerate treatment",
                        "Concomitant topical medications and cosmetics that have strong drying effect should be avoided; it is also advisable to \"rest\" a patient's skin until effects of such preparations subside before treatment is initiated",
                        "Drug should not be used on eczematous skin, as it may cause severe irritation",
                        "Weather extremes, such as wind or cold, may be more irritating to patients using the topical application"
                    ]
                },
                {
                    "type": "Photosensitivity and risk of sunburn",
                    "description": [
                        "Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided unless deemed medically necessary, and in such cases, exposure should be minimized during therapy",
                        "Patients must be warned to use sunscreens and protective clothing when using this drug; patients with sunburn should be advised not to use the topical application until fully recovered; patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using this drug",
                        "Administer with caution if patient is taking drugs known to be photosensitizers (eg, thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides)because of increased possibility of augmented photosensitivity",
                        "Use of sunscreens (minimum strength of SPF 15) and protective clothing recommended during use"
                    ]
                },
                {
                    "type": "Embryofetal toxicity",
                    "description": [
                        "This drug elicits malformations and developmental effects associated with retinoids after topical and oral administration to pregnant rats and rabbits during organogenesis; systemic exposure to tazarotenic acid is dependent upon extent of body surface area treated; in patients treated topically over sufficient body surface area, exposure could be in same order of magnitude as in orally treated animals",
                        "Although there may be less systemic exposure in treatment of acne of the face alone due to less surface area for application, this drug is a teratogenic substance and causes fetal malformations in animals, and it is not known what level of exposure is required for teratogenicity in humans"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Concomitant topical acne therapy should be used with caution because a cumulative irritant effect may occur; if irritancy or dermatitis occurs, reduce frequency of application or temporarily interrupt treatment and resume once the irritation subsides",
                        "Avoid concomitant dermatologic medications and cosmetics that have a strong drying effect; postpone treatment until the effects of these products subside before initiating treatment",
                        "Coadministration with oxidizing agents, such as benzoyl peroxide, may cause degradation of tazarotene and may reduce the clinical efficacy of tazarotene; if combination therapy is required, apply at different times of the day (eg, one in the morning and the other in the evening). "
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Application site pain",
            "percent": "5"
        },
        {
            "name": "Application site dryness",
            "percent": "4"
        },
        {
            "name": "Application site exfoliation",
            "percent": "2"
        },
        {
            "name": "Application site erythema",
            "percent": "2"
        },
        {
            "name": "Application site pruritus",
            "percent": "1"
        }
    ]
}